Range of neuropsychiatric disturbances in patients with Parkinson’s disease
- Dag Aarslanda,
- Jan P Larsenb,
- Neh Geok Lima,
- Carmen Janvina,
- Karen Karlsenb,
- Elise Tandbergb,
- Jeffrey L Cummingsc
- aSection of Geriatric Psychiatry, Rogaland Psychiatric Hospital, bDepartment of Neurology, Central Hospital of Rogaland, Stavanger, Norway, cDepartments of Neurology and Psychiatry and Biobehavioral Sciences, University of California at Los Angeles School of Medicine, and the Behavioral Neuroscience Section, Psychiatry Service, West Los Angeles Veterans Affairs Medical Center, USA
- Dr Dag Aarsland, Section of Geriatric Psychiatry, Rogaland Psychiatric Hospital, PO Box 1163, Hillevåg, N-4004 Stavanger, Norway. Telephone 0047 51515151; fax 0047 51515075; email
- Received 5 January 1999
- Revised 9 April 1999
- Accepted 20 April 1999
OBJECTIVES Disturbances of cognition and emotion are common in patients with Parkinson’s disease. Most previous studies of psychopathology in Parkinson’s disease have focused on a single psychiatric diagnosis or condition. The objective of this study was to describe the range of neuropsychiatric symptoms in a representative sample of patients with Parkinson’s disease.
METHODS The sample of 139 patients was drawn from an epidemiological study of Parkinson’s disease in Rogaland county, Norway, and represented 93% of those who had survived during the 4 years since the initial assessment. The diagnosis of Parkinson’s disease was based on published criteria. Neuropsychiatric symptoms were assessed using the neuropsychiatric inventory, a caregiver based structured interview, which assesses severity and frequency of 10 psychiatric symptoms present during the past month.
RESULTS At least one psychiatric symptom was reported in 61% of the sample. The most common behaviours were depression (38%) and hallucinations (27%), and the least common symptoms were euphoria and disinhibition. The highest mean scores were found for depression, apathy, and hallucinations. Factor analysis showed that hallucinations, delusions, and irritability clustered into one factor, and apathy and anxiety constituted another factor. Psychiatric symptoms were more common among patients living in nursing homes compared with home dwelling patients, and correlated with stage of disease and cognitive impairment, but not with age or duration of disease. No relation to left or right sided parkinsonism was found.
CONCLUSION This study emphasises the importance of psychiatric symptoms in Parkinson’s disease, which were present in most patients. Clinicians should focus on the emotional and cognitive disturbances in addition to the motor manifestations of the disease.
Patients with Parkinson’s disease have a range of neuropsychiatric symptoms as well as the motor manifestations of the disease. However, most previous studies on psychopathology in Parkinson’s disease have focused on one or few psychiatric diagnoses, such as depression,1psychosis,2 and cognitive impairment.3 Little is known about the range of neuropsychiatric syndromes occurring in patients assessed simultaneously for a wide range of cognitive and emotional disorders. Moreover, nearly all previous studies have used convenience samples of patients referred to clinical care for their motor symptoms.
In the most comprehensive study to date, Brown and MacCarthy4 used a standardised psychiatric interview designed to assess psychiatric disturbances in the general population to provide a detailed description of the psychiatric symptomatology in 40 patients with Parkinson’s disease. Seventy per cent of the patients exhibited at least one psychiatric syndrome, the most common conditions were depression and anxiety. However, only 10% of the patients warranted a psychiatric diagnosis, and these were all within the class “neurotic disorders”. The authors acknowledged that “analysis on the level of diagnostic category is probably unsuitable when considering patients with Parkinson’s disease”. Furthermore, the finding that 24 of the 37 psychiatric syndromes were not represented in the sample suggests that instruments aimed at identifying general psychiatric syndromes are not well suited for a population with a brain disorder such as Parkinson’s disease.
In the current study, we used an instrument specifically designed to assess psychopathology in patients with brain disorders, the neuropsychiatric inventory (NPI)5 to investigate the range of neuropsychiatric syndromes in a sample of patients with Parkinson’s disease. The NPI has proved validity and reliability in patients with dementia. It is a convenient instrument that assesses both the frequency and severity of 10 syndromes: delusions, hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, and abnormal motor output. The patient population assessed was demographically representative and was well characterised clinically and cognitively.
Patients and methods
Patients were recruited from an epidemiological study of Parkinson’s disease in Rogaland county, Norway. The study area has 220 000 inhabitants. Total ascertainment of patients with recognised idiopathic Parkinson’s disease in this defined geographical area was attempted. The main source of patient information was the files of the outpatient clinic of the Department of Neurology at the Central Hospital of Rogaland, that serves the entire area in a public health system. Additional sources were the main patient files of the hospital. These files included information on diagnosis of every inpatient referred to the hospital since 1972. Furthermore, all general practitioners, nursing homes, consulting physicians in charge of nursing homes, district nurses, and home health care workers in the study area were contacted in writing and asked for information on patients with symptoms of parkinsonism. Information on all members of the local branch of the Parkinson’s disease society was available as well. All nursing home physicians, district nurses and home health workers, and 75% of the general practitioners responded to the written inquiry. Based on these sources, nearly 500 patients were considered for a diagnostic evaluation. Based on information from the hospital records, some patients could be excluded because they did not have Parkinson’s disease. Nearly 400 patients were interviewed and examined by one of the neurologists in the study group, and 245 were diagnosed as having Parkinson’s disease. The baseline evaluation was carried out in 1992 and 1993.6 During 1996 and 1997, the survivors were invited to participate in the present study and assessed with a comprehensive evaluation consisting of three sessions: a neurological, psychiatric, and neuropsychological examination. The three evaluations were performed within 1 month of each other. To evaluate the representativeness of this follow up sample, comparisons with the baseline population were performed. The patients provided informed consent, and the study was approved by the regional ethics committee, University of Bergen.
Diagnosis and clinical evaluation of Parkinson’s disease
A semistructured interview was performed to obtain information on disease history, drug therapy, response to levodopa, and demographic variables. The clinical examination of motor symptoms consisted of a complete unified Parkinson’s disease rating scale (UPDRS) assessment7 including the Hoehn and Yahr scale.8 The diagnostic evaluation was based on clinical information at the primary evaluation, disease development, and response to levodopa. To achieve high diagnostic accuracy without losing sensitivity, a diagnostic classification defining clinical definite, probable, and possible Parkinson’s disease was used (see Larsen et al 9 for a description of the categories). The same assessment had been conducted during the evaluation 4 years previously. Other neurological diagnoses or use of neuroleptic drugs before the first diagnostic evaluation prohibited a diagnosis of Parkinson’s disease. In 40 patients CT or MRI of the brain was performed, without abnormalities compatible with diagnosis other than Parkinson’s disease. Patients with clinical fluctuations were examined in the “on state”.
The UPDRS motor scale was used to obtain scores for several clinical factors that might have an impact on psychiatric symptoms. We calculated a tremor score by adding scores on item 20 and 21 (tremor at rest and action or postural tremor of hands). Rigidity was measured by the scores on item 22, and akinesia by adding the scores on items 23-26 (finger taps, hand movements, rapid alternating movements of hand, and leg agility). We calculated right and left side motor subscores by adding the respective scores for right and left side on UPDRS items 20-26, and identified patients with right or left dominance by using a cut off score of ±3 or more on the difference between scores for the right and left sides.
A semistructured interview based on the diagnostic and statistical manual of mental disorders, third edition, revised10(DSM-III-R) criteria for dementia was administered to the caregiver by a psychiatrist with experience in geriatric psychiatry and neuropsychiatry (NGL and DA). Two brief cognitive screening instruments were administered to the patient by a research nurse: the mini mental state examination (MMSE)11 and the dementia rating scale (DRS).12 The DRS provides a total score and five subscores: attention, memory, categorisation, initiation and perseveration, and construction. Patients with an MMSE score of 16 or above performed a neuropsychological battery assessing the following cognitive domains: executive functioning (Stroop test), visual memory (Benton visual retention test), visuospatial functioning (judgement of line orientation test) and attention and vigilance. A group of healthy elderly controls (n=37) performed the cognitive screening and neuropsychological evaluation. The final diagnosis of dementia (yes, no, questionable) according to the DSM-III-R criteria was made by two of us (DA and JPL), based on the clinical interview, the cognitive screening, and the neuropsychological tests.
The 10 item version of the NPI was administered by one of the two psychiatrists (NGL and DA). For patients living in their homes, the NPI was administered to a family member familiar with the patient’s behaviour, usually the spouse. For patients living in nursing homes, the nurse or another staff member who knew the patient best was interviewed.
The NPI was administered following the procedures previously described.5 Screening questions for each of the 10 neuropsychiatric symptoms were posed first. If a positive response was obtained, then the symptom was explored with scripted questions that focused on specific features of the neuropsychiatric symptom. The caregiver then rated the symptom; scores from 1 through 4 were obtained for the frequency and 1 through 3 for the severity of each symptom. A composite score for each symptom was the product of the frequency and severity subscores (maximum=12). The composite score was used in the analysis.
Analyses consisted primarily of description of NPI scores and calculation of proportions. The relations of NPI scores to demographic and clinical variables were analysed using non-parametric tests (Spearman rank correlation and Mann-WhitneyU test). All p values are two tailed. A significance level of 0.01 was chosen due to a large number of comparisons.
CLINICAL AND DEMOGRAPHIC CHARACTERISTICS
Of the 245 patients evaluated in 1993, 88 had died, and seven subsequently had been diagnosed as not having Parkinson’s disease. Accordingly, 150 patients were invited to participate in the present study. Eleven subjects refused to participate, and hence a total of 139 patients (92.7% of the survivors with Parkinson’s disease) completed the follow up study. The male:female ratio was 61:78, the mean age was 74.4 (SD 7.9) years, and the duration of Parkinson’s disease was 12.6 (SD 5.1) years. Thirty six patients (26%) lived in a nursing home. Most were diagnosed as clinical definite Parkinson’s disease (n=104, 74.8% of the sample), 32 (23%) as probable Parkinson’s disease, and three (2.2%) as possible Parkinson’s disease. Ten patients (7.2%) were in Hoehn and Yahr stage 1 or 1.5, 40 (28.8%) in stage 2 or 2.5, 34 (24.5%) in stage 3, 32 (23%) in stage 4, and 21 (15.1%) in stage 5. (Data were missing for two patients). Fifty patients, 36% of the sample, met the DSM-III-R criteria for dementia, and eight had questionable dementia. The patients with dementia were significantly older than the non-demented patients (78.6 (SD 5.9) (p<0.001)). An MMSE score was obtained for 127 of the patients, and the mean score was 25.2 (SD 5.9). Nine of the 12 who did not complete the MMSE were too demented to perform the test. One hundred and twelve completed the DRS; the mean score was 127.5 (SD 22.4). Eighteen of the 27 non-completers were too demented to perform the test. The demographic and clinical characteristics of the study sample were similar to those in the population of patients with Parkinson’s disease from the evaluation in 1993, with the expected changes in conjunction with the evolution of more advanced disease.6
NEUROPSYCHIATRIC INVENTORY SCORES
Interrater reliability of the NPI was assessed by the two raters performing simultaneous ratings of 12 patients. Intraclass correlations between the two raters on the NPI items were high: hallucinations (0.94), depression (0.84), anxiety (0.94), apathy (0.84), aberrant motor behaviour (0.96), and total NPI score (0.93). All 10 symptoms were reported in the sample, but for the other items, too few symptoms were detected and thus the reliability data could not be calculated. Fifty four patients with Parkinson’s disease (39%) had no scorable symptoms on the NPI. Twenty two patients (16%) had one symptom, 28 (20%) had two, and 35 (25%) had three or more neuropsychiatric symptoms present. The most common behaviours were depression (present in 38% of the patients), hallucinations (27%), and anxiety (20%). The least common symptoms were euphoria (0.7%) and disinhibition (6.5%). The highest mean scores were found for depression, apathy, and hallucinations. When severity scores were calculated only for those patients in whom the symptom was present, the highest scores were obtained for apathy, aberrant motor behaviour, and anxiety. The scores and frequency of all symptoms are shown in the table.
RELATIONS AMONG NEUROPSYCHIATRIC INVENTORY SUBSCORES
High correlations were found among delusions, hallucinations, agitation, and irritability; and between apathy and anxiety. Depression correlated with both the psychotic and agitation symptoms and anxiety and apathy symptoms. A principal component factor analysis was performed to further explore the interrelation of the NPI symptoms. Consistent with the correlation analysis, two factors emerged with an eigenvalue of at least 1.5: factor 1 included the items delusion, hallucination, and irritability, and factor 2 included anxiety and apathy.
The relation between apathy and depression was explored in more detail. Six of the 23 patients with apathy (4.3% of the sample) had no evidence of depression (score of 0), whereas the remaining patients with apathy had positive scores on the depression subscale.
RELATION BETWEEN NPI SCORES AND CLINICAL AND DEMOGRAPHIC VARIABLES
The clinical and demographic correlates of neuropsychiatric symptoms in Parkinson’s disease were explored. Neither age or duration of disease nor levodopa dosage correlated with the NPI subscores. A relation between NPI scores and Hoehn and Yahr stage was found. Most behaviour scores increased with more advanced disease, and significant correlations with the Hoehn and Yahr stage were found for total NPI score (Spearman’s r=0.37, p<0.001), and delusion (r=0.38, p<0.001), hallucination (r=0.37, p <0. 001), agitation (r=0.28, p<0.001), and aberrant motor behaviour (r=0.28, p<0.001) scores. Patients in nursing homes had higher total NPI scores than home dwelling patients (U=1077, p<0.001), and this difference was primarily due to higher scores on the delusion, hallucination, agitation, and disinhibition subscales. Eighty three per cent of the nursing home population had at least one symptom present. Analysis of the relation between neuropsychiatric syndromes and sex showed somewhat more irritability among male patients (U=2033, p<0.005).
Scores of delusions, hallucinations, and agitation correlated significantly with the akinesia and rigidity scores (p<0.005). No other significant correlations were found between NPI subscores and scores of akinesia, rigidity, or tremor. Subscores for NPI did not differ between patients with predominantly right (n=26) or left sided (n=38) parkinsonism, but a non-significant trend towards a higher total NPI score in the left side group was found (U=373; p=0.087). Patients with probable and possible Parkinson’s disease showed a trend towards higher NPI total score (U=1375; p=0.03) and agitation score (U=1480, p=0.02) compared with patients with clinical definite Parkinson’s disease. There were no significant correlations between NPI scores and duration and level of disability caused by dyskinesias. “On-off” fluctuations were reported in 45% of the patients, but no relations between NPI subscores and fluctuations were found.
RELATION BETWEEN NPI SCORES AND COGNITIVE FUNCTIONS
A characteristic relation was found between NPI subscores and cognitive functions. Demented patients had more frequent and more severe neuropsychiatric morbidity as measured with the NPI total score compared with patients without dementia or with questionable dementia (U=1106, p<0.001). Significant relations with dementia were found for delusions (U=1545, p<0.001), hallucinations (U=1228, p<0.001), apathy (U=1570, p<0.05), and aberrant motor behaviour (U=1638, p<0.001). The relations between the NPI items and tests measuring different cognitive functions were also explored. A distinct pattern of relations emerged. Total NPI, hallucination, delusion, and agitation scores correlated with MMSE, most DRS subscales, and performance on memory tests. In addition, a significant correlation was found between apathy and the number of errors on the Stroop test, a measure of executive functioning.
The objective of this study was to explore the range and profile of the psychiatric morbidity in Parkinson’s disease, and to examine the relation between psychiatric symptoms and demographic and clinical variables. The main finding was that 61% of the sample showed at least one psychiatric symptom, and 45% had two or more. The proportion was particularly high among the Parkinson’s disease population living in nursing homes. Depression was the most common symptom, followed by hallucinations and anxiety. The highest scores were reported for apathy, anxiety, and depression. The rates found were similar to those reported in previous studies, focusing on depression,1hallucinations,2 anxiety,13 and apathy14 and are well above the frequencies found in the general, non-parkinsonian elderly population in Scandinavia15 16
The severity of psychiatric symptoms were associated with disease stage and cognitive impairment, but not with age, duration of disease, levodopa dose, dyskinesia, or on-off phenomena. These findings are in accordance with those reported by Brown and MacCarthy.4Depression did not correlate with clinical or cognitive variables although it was more often present in those with other neuropsychiatric symptoms. The lack of association between depression and disease stage is in accordance with previous studies,1 17 18 and suggests that the mood changes in Parkinson’s disease are not a reaction to motor disability but rather reflect a neurobiologically based disorder of emotional functions. The previously reported relation between depression and akinetic-rigid subtype17 and right sided Parkinson’s disease19 were not replicated in this study.
To our knowledge, only one previous study has investigated the range of psychiatric morbidity in Parkinson’s disease.4 Compared with the general population of patients with Parkinson’s disease,6 the sample in that study was a highly selected convenience group, with a lower age and few men. Furthermore, they were cognitively intact and had a more restricted range of severity of disease, two factors which probably influenced the range and severity of psychiatric morbidity. Our sample was more representative, but included only patients with a disease duration of at least 4 years. However, as both studies showed, duration of disease did not seem to influence psychiatric morbidity. Different methods for assessing psychiatric symptoms were used in the two studies. In the current study, the NPI was used, an instrument designed to identify psychiatric morbidity in patients with neurological disorders.5Nevertheless, the findings in these two studies regarding the rate of psychiatric morbidity in general are similar, and show a high prevalence of psychiatric morbidity in patients with Parkinson’s disease.
The study has methodological shortcomings which need to be recognised when interpreting the findings. Because we did not include a control group, the exact prevalence of psychiatric symptoms specific to Parkinson’s disease cannot be estimated with certainty. However, other studies suggest that patients without brain disease have very low frequencies of NPI symptoms present,5 indicating that most of the psychiatric morbidity is in fact caused by Parkinson’s disease. The sample is drawn from the survivors of a population of patients with Parkinson’s disease, but the sample is skewed towards patients with a long duration of disease and thus with more advanced illness. This might have increased the prevalence of psychiatric symptoms. The strengths of the study are the relatively large sample, including institutionalised and severely ill patients, and the comprehensive evaluation battery including a standardised assessment of neuropsychiatric symptoms with high validity and reliability.
The psychiatric symptoms clustered into two groups, which had different relations with the cognitive and motor domains of the disease. One group of symptoms included delusions, hallucinations, agitation, and irritability. These symptoms correlated with levels of akinesia and rigidity, and with impairment on general cognitive measures such as the MMSE score and memory. Another cluster of symptoms were apathy and anxiety. Apathy usually occurred together with depression, consistent with other studies.14 20 This is different from the findings in other neurobehavioural disorders such as progressive supranuclear palsy and Alzheimer’s disease, in which apathy is less associated with depression.20 Apathy was also associated with impairment of executive functions. The pattern of relation between emotional and cognitive abnormalities in Parkinson’s disease suggests that psychosis is related to abnormalities of temporolimbic structures mediating mnemonic functions, whereas disturbances of frontal systems, also mediating executive skills, might account for the occurrence of apathy. Psychosis was more common in patients meeting criteria for dementia than in those with preserved cognition. In the initial phase of this study, we found that patients with Parkinson’s disease with dementia were more likely to exhibit psychotic symptoms,21similar to other investigations.22 This may reflect the presence of cortical Lewy bodies in the paralimbic cortex or more marked cholinergic deficits found in these patients.
In conclusion, the present study shows a high prevalence of psychiatric morbidity among patients with Parkinson’s disease. The rate of reported neuropsychiatric features is comparable with that reported in other brain diseases, such as progressive supranuclear palsy,23 Huntington’s disease,24frontotemporal dementia,25 and Alzheimer’s disease.26 However, the pattern of psychiatric symptoms differs among different brain disorders, reflecting the involvement of different brain regions and different transmitter systems. Clinicopathological or imaging studies are needed to clarify these relations in more detail. This study emphasises the importance of psychiatric symptoms in Parkinson’s disease, which were present in most patients. Clinicians should focus on the emotional and cognitive disturbances as well as the motor manifestations of the disease.
This project was supported by the Research Councils of the Central and Psychiatric Hospitals of Rogaland, a Scandinavian Society of Psychopharmacology grant, NIA Alzheimer’s Disease Center grant AG10123, an Alzheimer’s Disease Center of California grant, and the Sidell-Kagin Foundation.